Van de Werf F
Department of Cardiology, University of Leuven, Belgium.
Thromb Haemost. 1997 Jul;78(1):210-3.
Glycoprotein IIb/IIIa receptor antagonists are more potent platelet inhibitors than aspirin. Although important reductions in ischemic/thrombotic complications have been observed with these agents following coronary interventions, their potential value for the medical treatment of acute coronary syndromes is at present uncertain. The final results of large randomized studies in patients with acute coronary syndromes are eagerly awaited.
糖蛋白IIb/IIIa受体拮抗剂是比阿司匹林更强效的血小板抑制剂。尽管在冠状动脉介入治疗后使用这些药物已观察到缺血/血栓并发症有显著减少，但其在急性冠状动脉综合征药物治疗中的潜在价值目前尚不确定。人们急切期待着针对急性冠状动脉综合征患者的大型随机研究的最终结果。
